×
About 103 results

ALLMedicine™ Lung Cancer Immunotherapy Center

Research & Reviews  28 results

Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon.
https://doi.org/10.1016/j.ctrv.2021.102308
Cancer Treatment Reviews; Passiglia F, Bertaglia V et. al.

Nov 11th, 2021 - We are witnessing a silent revolution in the treatment of early stage non-small cell lung cancer (NSCLC), with a series of practice-changing clinical trials enriching the therapeutic perspectives of lung cancer patients with potentially curable di...

Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy.
https://doi.org/10.1080/14737140.2021.1996230
Expert Review of Anticancer Therapy; Behrouzieh S, Sheida F et. al.

Oct 24th, 2021 - Lung cancer is known for its high mortality rate and prevalence in the world today. For decades, chemotherapy has been used as the main treatment for this cancer, but this has changed over time. Immune checkpoint inhibitors (ICIs) such as programm...

Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive v...
https://doi.org/10.1007/s11864-021-00891-8 10.1126/science.aar4060 10.1186/s13045-020-00862-w 10.3389/fimmu.2019.00999 10.1016/j.ccell.2020.07.004 10.1186/s40364-020-00209-0 10.1158/1078-0432.CCR-17-2156 10.1053/j.seminoncol.2015.05.011 10.1158/2326-6066.CIR-18-0277 10.1186/s40425-019-0799-2 10.1186/s40364-020-00228-x 10.1158/2159-8290.CD-14-1236 10.1038/s41571-019-0173-9 10.1038/nature06030 10.1002/humu.20253 10.1038/sj.onc.1210594 10.1038/onc.2011.98 10.1097/JTO.0000000000000056 10.21037/tlcr.2016.10.08 10.3390/cancers10040088 10.1038/s42003-020-1092-0 10.18632/oncotarget.6379 10.1126/scisignal.2004088 10.1016/j.jtho.2016.02.009 10.1158/1078-0432.CCR-14-3112 10.1038/sj.onc.1203227 10.1038/sj.onc.1210418 10.1038/nrc2676 10.1073/pnas.0308061100 10.3892/mmr.2014.1916 10.18632/oncotarget.12334 10.1038/sj.emboj.7600110 10.1158/0008-5472.CAN-07-2989 10.1016/j.lungcan.2010.02.004 10.1038/ncb3255 10.1016/j.ccell.2015.04.001 10.1016/j.freeradbiomed.2010.09.006 10.1158/2159-8290.CD-18-1237 10.4049/jimmunol.1100367 10.1111/j.1600-065X.2012.01150.x.Metabolic 10.1002/eji.200939677 10.1038/ncomms15876 10.1038/s41467-018-07545-8 10.1074/jbc.M114.616441 10.1200/po.18.00210 10.1016/j.lungcan.2020.11.006 10.1164/rccm.201510-2031OC 10.1038/onc.2015.375 10.1158/0008-5472.CAN-15-1439 10.1016/j.celrep.2016.12.059 10.1073/pnas.0704677104 10.1016/j.cell.2017.11.013 10.1093/annonc/mdw436 10.1158/2159-8290.CD-18-1286 10.1038/nri3921 10.1038/s41467-020-19288-6 10.1016/j.jtho.2020.01.009 10.1016/j.celrep.2015.04.031 10.1126/science.aba6098 10.1126/science.abb4255 10.1074/jbc.M110.190660 10.1038/ng.98 10.1126/science.1090922 10.3892/br.2018.1122 10.1073/pnas.1004952107 10.1038/ncomms4261 10.1126/science.1062074 10.1172/JCI75371 10.1158/1078-0432.CCR-16-2410 10.1200/jco.2020.38.15_suppl.9033 10.1200/jco.2020.38.15_suppl.e15055 10.1158/1078-0432.CCR-18-0163 10.1200/jco.2018.36.15_suppl.3028 10.1016/S1470-2045(18)30144-X 10.1016/j.annonc.2020.02.006 10.1200/jco.2019.37.15_suppl.102 10.1016/j.jtho.2019.08.591 10.1371/journal.pone.0238358 10.1200/jco.2020.38.15_suppl.e21548 10.1016/j.lungcan.2021.02.010 10.1016/j.jtho.2019.08.428 10.1200/jco.2020.38.15_suppl.e15082 10.1097/MD.0000000000022323 10.1158/1538-7445.am2020-lb-397 10.1136/esmoopen-2020-000706 10.1016/j.annonc.2020.08.1579 10.1200/po.18.00326 10.1200/jco.2020.38.15_suppl.e15135 10.1200/jco.2020.38.15_suppl.e15113 10.1016/j.jtho.2021.01.321 10.1016/s1556-0864(21)01941-9 10.1038/s41586-019-1694-1 10.1056/NEJMoa1507643 10.1016/S2213-2600(19)30084-0
Current Treatment Options in Oncology; Mazzaschi G, Leonetti A et. al.

Sep 16th, 2021 - The quest for immunotherapy (IT) biomarkers is an element of highest clinical interest in both solid and hematologic tumors. In non-small-cell lung cancer (NSCLC) patients, besides PD-L1 expression evaluation with its intrinsic limitations, tissue...

PDL-1 expression in lung carcinoma and its correlation with clinicopathological and pro...
https://doi.org/10.1080/15321819.2021.1938606
Journal of Immunoassay & Immunochemistry; Farrag M, Ibrahim E et. al.

Jun 10th, 2021 - Lung cancers have high incidence and high mortality rates. The immune checkpoints as programmed death ligand 1 (PDL-1) can suppress the tumor immune reaction. So, their blocking seems to be a way to treat tumors. This study assesses PDL-1 immunohi...

Overview of Lung Cancer Immunotherapy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175029
Cancer Journal (Sudbury, Mass.); Sanmamed MF, Eguren-Santamaria I et. al.

Dec 11th, 2020 - Anti-PD-(L)1 therapy represents a turning point in lung cancer immunotherapy, moving from previously ineffective enhancer strategies to immune checkpoints as standard first- and second-line therapies. This unprecedented success highlights the impo...

see more →

News  13 results

Babies' Turn for COVID Vax; More States Ditch Mask Mandates; Olympian Found Doping
https://www.medpagetoday.com/infectiousdisease/covid19/97116

Feb 10th, 2022 - Note that some links may require registration or subscription. Kids under 5 years of age may be able to get the Pfizer/BioNTech COVID vaccine as early as President's Day. (Reuters) We're at the end of the "full-blown" phase of the pandemic, accord...

"Advancing Hope": SITC Designs Innovative Educational Experience for the Management of NSCLC
https://www.onclive.com/view/advancing-hope-sitc-designs-innovative-educational-experience-for-the-management-of-nsclc

Jan 18th, 2022 - CME activity for physicians and nurses is available at: cmeuniversity.com Lung cancer alone accounts for 26.5% of all cancer-related mortalities in the United States,1 which is more than any other malignancy. Despite increased awareness that smoki...

Novel Combination Immunotherapy Developed at Hollings Cancer Center to be Offered in Lung-MAP Trial
https://www.onclive.com/view/novel-combination-immunotherapy-developed-at-hollings-cancer-center-to-be-offered-in-lung-map-trial

Oct 20th, 2021 - A bench-to-bedside-pioneered lung cancer immunotherapy developed at MUSC Hollings Cancer Center is to be included in one of the largest lung cancer clinical trials being offered by the National Cancer Institute. Hollings researcher and MUSC Healt...

Evidence Grows for Tumor Mutational Burden as Predictor of Immunotherapy Success
https://www.onclive.com/view/evidence-grows-for-tumor-mutational-burden-as-predictor-of-immunotherapy-success

Dec 5th, 2020 - Garrett Frampton, PhD An unmet need exists for biomarkers that can identify response to PD-1/PD-L1 blockade as well as other immunotherapies. Tumor mutational burden (TMB), a measure of the total number of somatic mutations per million bases of c...

Top 5 Advances in Lung Cancer Immunotherapy Over the Past Decade
https://www.medscape.com/viewarticle/924067

Jan 23rd, 2020 - We've just come to the end of a remarkable decade of progress that has transformed how we treat—and, indeed, even how we view—lung cancer. Rewind 10 years: As we entered 2010, median survival for patients with metastatic non-small cell lung cancer...

see more →